Combination pharmacotherapy offers substantial therapeutic advantages but also poses substantial risks of adverse drug reactions (ADRs). The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and precision medicine. However, managing ADRs remains a challenge due to the vast search space of drug combinations and the complexity of physiological responses. Current graph-based architectures often struggle to effectively integrate multi-scale biological information and frequently rely on fixed association matrices, which limits their ability to capture dynamic organ-level dependencies and generalize across diverse datasets. Here we propose CrossADR, a hierarchical framework for organ-level ADR prediction through cross-layer feature integration and cross-level associative learning. It incorporates a gated-residual-flow graph neural network to fuse multi-scale molecular features and utilizes a learnable ADR embedding space to dynamically capture latent biological correlations across 15 organ systems. Systematic evaluation on the newly constructed CrossADR-Dataset-covering 1,376 drugs and 946,000 unique combinat
Early diagnosis is important for type 2 diabetes (T2D) to improve patient prognosis, prevent complications and reduce long-term treatment costs. We present a novel risk profiling approach based exclusively on health expenditure data that is available to Belgian mutual health insurers. We used expenditure data related to drug purchases and medical provisions to construct models that predict whether a patient will start glucose-lowering pharmacotherapy in the coming years, based on that patient's recent medical expenditure history. The design and implementation of the modeling strategy are discussed in detail and several learning methods are benchmarked for our application. Our best performing model obtains between 74.9% and 76.8% area under the ROC curve, which is comparable to state-of-the-art risk prediction approaches for T2D based on questionnaires. In contrast to other methods, our approach can be implemented on a population-wide scale at virtually no extra operational cost. Possibly, our approach can be further improved by additional information about some risk factors of T2D that is unavailable in health expenditure data.
Introduction: Real-world data generated from clinical practice can be used to analyze the real-world evidence (RWE) of COVID-19 pharmacotherapy and validate the results of randomized clinical trials (RCTs). Machine learning (ML) methods are being used in RWE and are promising tools for precision-medicine. In this study, ML methods are applied to study the efficacy of therapies on COVID-19 hospital admissions in the Valencian Region in Spain. Methods: 5244 and 1312 COVID-19 hospital admissions - dated between January 2020 and January 2021 from 10 health departments, were used respectively for training and validation of separate treatment-effect models (TE-ML) for remdesivir, corticosteroids, tocilizumab, lopinavir-ritonavir, azithromycin and chloroquine/hydroxychloroquine. 2390 admissions from 2 additional health departments were reserved as an independent test to analyze retrospectively the survival benefits of therapies in the population selected by the TE-ML models using cox-proportional hazard models. TE-ML models were adjusted using treatment propensity scores to control for pre-treatment confounding variables associated to outcome and further evaluated for futility. ML archite
Stroke is a leading cause of disability and death worldwide, with ischemic strokes accounting for nearly 80% of cases. Fewer than 5% of patients receive the sole validated pharmacotherapy, intravenous thrombolysis, highlighting the urgent need for novel therapies. Within this landscape, the exploration of natural molecules emerges as a promising avenue, particularly as a means to address limitations associated with conventional drugs. Nutraceuticals, bioactive compounds derived from food sources, offer a compelling prospect for health and wellness. The term nutraceutical reflects their dual potential in nutrition and pharmacotherapy, emphasizing their relevance to both disease prevention and treatment. Interestingly, many were initially recognized as ''natural preconditioners'', substances that prime the body for protection against stress or damage. In fact, numerous nutraceuticals have been shown to activate protective pathways similar to those triggered by preconditioning across various organs. Among nutraceuticals, omega-3 polyunsaturated fatty acids sourced from plants or fish, along with polyphenols, have emerged as particularly promising. Their consumption has been associated
Adverse drug reactions (ADRs) are a major barrier to safe and effective pharmacotherapy and increasingly reflect higher order interactions between drugs, genetic background, and clinical phenotypes. Existing graph based approaches usually predict ADRs as properties of drugs or drug pairs, leaving the causal gene implicit and limiting their value for pharmacogenomic decision making. We introduce HyperADRs, a hierarchical hypergraph framework that predicts ADR risk at the level of drug-gene-ADR triads. Starting from curated pharmacogenomic annotations in PharmGKB and the pharmacogenomics subdatabase of DrugBank, we construct high confidence triplets and integrate them with auxiliary molecular, functional, and disease relations from precision-medicine-oriented knowledge graphs. Drugs, genes, and ADR concepts are embedded with modality appropriate pretrained models (UniMol, ESM2, SapBERT) and propagated through a hypergraph convolutional network. A FiLM based, query conditioned contrastive learning module learns context specific representations so that, given any two entities, the model retrieves the correct third entity against many candidates. To improve robustness and interpretabili
Accurate dose-response forecasting under sparse sampling is central to precision pharmacotherapy. We present the Amortized In-Context Mixed-Effect Transformer (AICMET) model, a transformer-based latent-variable framework that unifies mechanistic compartmental priors with amortized in-context Bayesian inference. AICMET is pre-trained on hundreds of thousands of synthetic pharmacokinetic trajectories with Ornstein-Uhlenbeck priors over the parameters of compartment models, endowing the model with strong inductive biases and enabling zero-shot adaptation to new compounds. At inference time, the decoder conditions on the collective context of previously profiled trial participants, generating calibrated posterior predictions for newly enrolled patients after a few early drug concentration measurements. This capability collapses traditional model-development cycles from weeks to hours while preserving some degree of expert modelling. Experiments across public datasets show that AICMET attains state-of-the-art predictive accuracy and faithfully quantifies inter-patient variability -- outperforming both nonlinear mixed-effects baselines and recent neural ODE variants. Our results highligh
Population pharmacokinetic (PopPK) modelling is a fundamental tool for understanding drug behaviour across diverse patient populations and enabling personalized dosing strategies to improve therapeutic outcomes. A key challenge in PopPK analysis lies in identifying and modelling covariates that influence drug absorption, as these relationships are often complex and nonlinear. Traditional methods may fail to capture hidden patterns within the data. In this study, we propose a data-driven, model-free framework that integrates Variational Autoencoders (VAEs) deep learning model and LASSO regression to uncover key covariates from simulated tacrolimus pharmacokinetic (PK) profiles. The VAE compresses high-dimensional PK signals into a structured latent space, achieving accurate reconstruction with a mean absolute percentage error (MAPE) of 2.26%. LASSO regression is then applied to map patient-specific covariates to the latent space, enabling sparse feature selection through L1 regularization. This approach consistently identifies clinically relevant covariates for tacrolimus including SNP, age, albumin, and hemoglobin which are retained across the tested regularization strength levels,
Several studies showed that Large Language Models (LLMs) can answer medical questions correctly, even outperforming the average human score in some medical exams. However, to our knowledge, no study has been conducted to assess the ability of language models to validate existing or generated medical text for correctness and consistency. In this paper, we introduce MEDEC (https://github.com/abachaa/MEDEC), the first publicly available benchmark for medical error detection and correction in clinical notes, covering five types of errors (Diagnosis, Management, Treatment, Pharmacotherapy, and Causal Organism). MEDEC consists of 3,848 clinical texts, including 488 clinical notes from three US hospital systems that were not previously seen by any LLM. The dataset has been used for the MEDIQA-CORR shared task to evaluate seventeen participating systems [Ben Abacha et al., 2024]. In this paper, we describe the data creation methods and we evaluate recent LLMs (e.g., o1-preview, GPT-4, Claude 3.5 Sonnet, and Gemini 2.0 Flash) for the tasks of detecting and correcting medical errors requiring both medical knowledge and reasoning capabilities. We also conducted a comparative study where two m
PHF5A is a member of the zinc-finger proteins. To advance knowledge on their role in carcinogenesis, data from experimental studies, animal models and clinical studies in different tumorigenesis have been reviewed. Furthermore, PHF5A as an oncogenic function, is frequently expressed in tumor cells and a potential prognostic marker for different cancers. PHF5A is implicated in the regulation of cancer cell proliferation, invasion, migration and metastasis. Knockdown of PHF5A prevented the invasion and metastasis of tumor cells. Here, the role of PHF5A in different cancers and their possible mechanism in relation to recent literature is reviewed and discussed. However, there is an open promising perspective to their therapeutic management for different cancer types.
As a solution to methodologic challenges inherent to estimating causal effects of exposures in early pregnancy, we suggest emulating a target trial using a treatment decision design, wherein time zero is centered around clinical landmarks where treatment decisions may occur, such as the date of preconception counseling or prenatal care initiation. These ideas are illustrated via protocols for two target trials in large administrative databases, antidepressant use for pre-existing depressive disorder and antihypertensive medication use for mild-to-moderate chronic hypertension. Careful consideration of these issues is critical to the identification of the causal effects of early-pregnancy pharmacotherapies on pregnancy outcomes.
Transcranial photobiomodulation is an optical method for non-invasive brain stimulation. The method projects red and near-infrared light through the scalp within 600-1100 nm and low energy within the 1-20 J/cm2 range. Recent studies have been optimistic about replacing this method with pharmacotherapy and invasive brain stimulation. However, concerns and ambiguities exist regarding the light penetration depth and possible thermal side effects. While the literature survey indicates that the skin temperature rises after experimental optical brain stimulation, inadequate evidence supports a safe increase in temperature or the amount of light penetration in the cortex. Therefore, we aimed to conduct a comprehensive study on the heat transfer of near-infrared stimulation for the human brain. Our research considers the transcranial photobiomodulation over the human brain model by projecting 810 nm light with 100 mW/cm2 power density to evaluate its thermal and optical effects using bioheat transfer and radiative transfer equation. Our results confirm that the near-infrared light spectrum has a small incremental impact on temperature and approximately penetrates 1 cm, reaching the cortex.
There is mounting evidence of a link between the properties of electroencephalograms (EEGs) of depressive patients and the outcome of pharmacotherapy. The goal of this study was to develop an EEG biomarker of antidepressant treatment response which would require only a single EEG measurement. We recorded resting, 21-channel EEG in 17 inpatients suffering from bipolar depression in eyes closed and eyes open conditions. The EEG measurement was performed at the end of the short washout period which followed previously unsuccessful pharmacotherapy. We calculated the normalized wavelet power of alpha rhythm using two referential montages and an average reference montage. In particular, in the occipital (O1, O2, Oz) channels the wavelet power of responders was up to 84% higher than that of nonresponders. Using a novel classification algorithm we were able to correctly predict the outcome of treatment with 90% sensitivity and 100% specificity. The proposed biomarker requires only a single EEG measurement and consequently is intrinsically different from biomarkers which exploit the changes in prefrontal EEG induced by pharmacotherapy over a given time.
For many types of learning, spaced training that involves repeated long inter-trial intervals (ITIs) leads to more robust memory formation than does massed training that involves short or no intervals. Several cognitive theories have been proposed to explain this superiority, but only recently has data begun to delineate the underlying cellular and molecular mechanisms of spaced training. We review these theories and data here. Computational models of the implicated signaling cascades have predicted that spaced training with irregular ITIs can enhance learning. This strategy of using models to predict optimal spaced training protocols, combined with pharmacotherapy, suggests novel ways to rescue impaired synaptic plasticity and learning.
Doctors and Pharmacists play a foremost role in safe, effective use of medication in health care. Still, there is no database available through which Doctor can communicate with all field of pharmacy such as hospital Pharmacy, Clinical Pharmacy, Community Pharmacy, Nutrition Pharmacy and Drug research center so that they would like to cooperate with pharmacists in Medication error prevention, Drug-Disease management, Nutrition management, and pharmacotherapy. The authors examined the comprehensive project of implementing Electronic Drug Information Record (EDIR), introduce the new term Pharmacybernetic and how to reduce the medication error by integrated management system (IMS). This paper presented EDIR conceptual model and the flow sheet of the Pharmacybernetic system, which describes the integration of different Pharmaceutical related aspect in the field of Cybernetic.
This paper presents the results of our recent work on studying the effects of deep brain stimulation (DBS) and medication on the dynamics of brain local field potential (LFP) signals used for behavior analysis of patients with Parkinson s disease (PD). DBS is a technique used to alleviate the severe symptoms of PD when pharmacotherapy is not very effective. Behavior recognition from the LFP signals recorded from the subthalamic nucleus (STN) has application in developing closed-loop DBS systems, where the stimulation pulse is adaptively generated according to subjects performing behavior. Most of the existing studies on behavior recognition that use STN-LFPs are based on the DBS being off. This paper discovers how the performance and accuracy of automated behavior recognition from the LFP signals are affected under different paradigms of stimulation on/off. We first study the notion of beta power suppression in LFP signals under different scenarios (stimulation on/off and medication on/off). Afterward, we explore the accuracy of support vector machines in predicting human actions (button press and reach) using the spectrogram of STN-LFP signals. Our experiments on the recorded LFP
Medication adherence is a major problem for patients with chronic diseases that require long term pharmacotherapy. Many unanswered questions surround adherence, including how adherence rates translate into treatment efficacy and how missed doses of medication should be handled. To address these questions, we formulate and analyze a mathematical model of the drug concentration in a patient with imperfect adherence. We find exact formulas for drug concentration statistics, including the mean, the coefficient of variation, and the deviation from perfect adherence. We determine how adherence rates translate into drug concentrations, and how this depends on the drug half-life, the dosing interval, and how missed doses are handled. While clinical recommendations require extensive validation and should depend on drug and patient specifics, as a general principle our theory suggests that nonadherence is best mitigated by taking double doses following missed doses if the drug has a long half-life. This conclusion contradicts some existing recommendations that cite long drug half-lives as the reason to avoid a double dose after a missed dose. Furthermore, we show that a patient who takes dou